Biomaterial Database

Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. 2022

Paulus Rommer, and Uwe K Zettl

Department of Neurology, Medical University of Vienna, Vienna, Austria.

There are few diseases where as much therapeutic progress has been made in recent years as in multiple sclerosis. Nine different drug classes with more than a dozen approved therapies are now available. Similarly, there have been unimaginable advances in understanding neuromyelitis optica (now neuromyelitis optica spectrum disorder [NMOSD]) over the past 15 years. Building on the knowledge gained, the first therapies have been approved in recent years. In this review, we aim to present all therapies approved for the treatment of MS or NMOSD. The different forms of application, different approval criteria and most important side effects will be presented. This work is intended for physicians who are interested in MS and NMOSD therapies and want to get a first overview and does not replace the respective guidelines of the regulatory authorities.

UI	MeSH Term	Description	Entries
D009103	Multiple Sclerosis	An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D009471	Neuromyelitis Optica	A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.	Devic Disease,Devic's Neuromyelitis Optica,Devic Neuromyelitis Optica,Devic Syndrome,Devic's Disease,Devic's Syndrome,NMO Spectrum Disorder,Neuromyelitis Optica (NMO) Spectrum Disorder,Neuromyelitis Optica (NMO) Spectrum Disorders,Neuromyelitis Optica Spectrum Disorder,Neuromyelitis Optica Spectrum Disorders,Devic Neuromyelitis Opticas,Devics Disease,Devics Neuromyelitis Optica,Devics Syndrome,Disease, Devic,Disease, Devic's,NMO Spectrum Disorders,Neuromyelitis Optica, Devic,Neuromyelitis Optica, Devic's,Neuromyelitis Opticas, Devic,Syndrome, Devic,Syndrome, Devic's
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man